| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penis | 52 | 2018 | 90 | 9.240 |
Why?
|
| Erectile Dysfunction | 20 | 2022 | 38 | 6.320 |
Why?
|
| Penile Induration | 21 | 2018 | 25 | 5.350 |
Why?
|
| Stem Cells | 13 | 2022 | 141 | 3.830 |
Why?
|
| Nitric Oxide Synthase | 27 | 2010 | 128 | 3.400 |
Why?
|
| Phosphodiesterase Inhibitors | 13 | 2012 | 34 | 2.990 |
Why?
|
| Transforming Growth Factor beta | 22 | 2008 | 197 | 2.980 |
Why?
|
| Muscle, Skeletal | 20 | 2013 | 282 | 2.560 |
Why?
|
| Fibrosis | 26 | 2011 | 159 | 2.500 |
Why?
|
| Stem Cell Transplantation | 6 | 2019 | 31 | 2.430 |
Why?
|
| Rats | 60 | 2020 | 3483 | 2.230 |
Why?
|
| Impotence, Vasculogenic | 7 | 2012 | 13 | 2.220 |
Why?
|
| Penile Erection | 16 | 2017 | 26 | 2.220 |
Why?
|
| Dyslipidemias | 3 | 2022 | 43 | 2.110 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2018 | 94 | 1.870 |
Why?
|
| Piperazines | 8 | 2012 | 111 | 1.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2020 | 643 | 1.750 |
Why?
|
| Myostatin | 18 | 2017 | 63 | 1.720 |
Why?
|
| Sulfones | 8 | 2012 | 44 | 1.620 |
Why?
|
| Animals | 83 | 2020 | 15081 | 1.590 |
Why?
|
| Rats, Inbred F344 | 26 | 2013 | 245 | 1.590 |
Why?
|
| Male | 92 | 2022 | 20025 | 1.450 |
Why?
|
| Muscle, Smooth | 15 | 2018 | 58 | 1.370 |
Why?
|
| Aging | 16 | 2015 | 664 | 1.370 |
Why?
|
| Nitric Oxide Synthase Type II | 16 | 2018 | 115 | 1.320 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2017 | 86 | 1.240 |
Why?
|
| Transforming Growth Factor beta1 | 9 | 2014 | 93 | 1.230 |
Why?
|
| Gene Expression | 11 | 2017 | 674 | 1.100 |
Why?
|
| Immunohistochemistry | 20 | 2017 | 893 | 1.090 |
Why?
|
| Rats, Zucker | 8 | 2020 | 23 | 1.000 |
Why?
|
| Thiazolidinediones | 3 | 2010 | 50 | 0.980 |
Why?
|
| Ethanol | 2 | 2016 | 192 | 0.970 |
Why?
|
| Benzhydryl Compounds | 2 | 2013 | 43 | 0.900 |
Why?
|
| Cell Differentiation | 12 | 2018 | 587 | 0.870 |
Why?
|
| Phenols | 2 | 2013 | 80 | 0.870 |
Why?
|
| Fibroblasts | 9 | 2009 | 272 | 0.820 |
Why?
|
| Blotting, Western | 16 | 2009 | 859 | 0.810 |
Why?
|
| Muscle Fibers, Skeletal | 4 | 2013 | 64 | 0.800 |
Why?
|
| Apoptosis | 14 | 2020 | 1398 | 0.780 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 1371 | 0.770 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2020 | 1 | 0.750 |
Why?
|
| Palmitic Acid | 1 | 2020 | 24 | 0.730 |
Why?
|
| Kidney Tubules | 2 | 2010 | 33 | 0.700 |
Why?
|
| Receptors, Androgen | 8 | 2005 | 126 | 0.690 |
Why?
|
| Urinary Incontinence | 1 | 2019 | 15 | 0.690 |
Why?
|
| Obesity | 3 | 2020 | 1067 | 0.690 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2017 | 130 | 0.680 |
Why?
|
| Cholesterol | 1 | 2020 | 205 | 0.670 |
Why?
|
| Testosterone | 9 | 2015 | 193 | 0.660 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2018 | 5 | 0.660 |
Why?
|
| Collagen | 7 | 2014 | 172 | 0.630 |
Why?
|
| Oxidative Stress | 9 | 2015 | 938 | 0.620 |
Why?
|
| Vagina | 3 | 2009 | 81 | 0.620 |
Why?
|
| Hypoglycemic Agents | 3 | 2010 | 160 | 0.620 |
Why?
|
| Cells, Cultured | 12 | 2020 | 1518 | 0.580 |
Why?
|
| Carbolines | 2 | 2007 | 15 | 0.580 |
Why?
|
| Muscle Development | 4 | 2013 | 45 | 0.570 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 485 | 0.570 |
Why?
|
| Mesoderm | 2 | 2008 | 70 | 0.560 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 67 | 0.560 |
Why?
|
| RNA, Small Interfering | 3 | 2008 | 409 | 0.550 |
Why?
|
| Mice | 21 | 2013 | 5913 | 0.550 |
Why?
|
| Molsidomine | 2 | 2012 | 4 | 0.540 |
Why?
|
| Humans | 51 | 2022 | 37093 | 0.530 |
Why?
|
| RNA, Messenger | 17 | 2014 | 1207 | 0.530 |
Why?
|
| Gene Transfer Techniques | 2 | 2006 | 47 | 0.520 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 3 | 2010 | 8 | 0.510 |
Why?
|
| Myoblasts | 4 | 2009 | 27 | 0.510 |
Why?
|
| Nitric Oxide | 10 | 2015 | 316 | 0.510 |
Why?
|
| Arginine | 5 | 2006 | 73 | 0.510 |
Why?
|
| Breast | 1 | 2016 | 135 | 0.500 |
Why?
|
| Purines | 6 | 2012 | 38 | 0.490 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2013 | 19 | 0.470 |
Why?
|
| Muscle Proteins | 3 | 2003 | 51 | 0.460 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2007 | 623 | 0.450 |
Why?
|
| Endocrine Disruptors | 1 | 2013 | 39 | 0.440 |
Why?
|
| Muscle Denervation | 1 | 2012 | 4 | 0.440 |
Why?
|
| Epithelial Cells | 1 | 2016 | 384 | 0.430 |
Why?
|
| DNA, Complementary | 5 | 2004 | 191 | 0.430 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 56 | 0.430 |
Why?
|
| Nitric Oxide Synthase Type I | 9 | 2013 | 56 | 0.420 |
Why?
|
| Weightlessness | 2 | 2002 | 16 | 0.410 |
Why?
|
| Gene Expression Regulation | 8 | 2016 | 1015 | 0.390 |
Why?
|
| Antifibrinolytic Agents | 1 | 2010 | 3 | 0.380 |
Why?
|
| Multipotent Stem Cells | 2 | 2008 | 16 | 0.380 |
Why?
|
| Androgens | 4 | 2004 | 89 | 0.370 |
Why?
|
| Prostatectomy | 2 | 2007 | 63 | 0.370 |
Why?
|
| Adipocytes | 3 | 2005 | 58 | 0.370 |
Why?
|
| Myocardium | 1 | 2012 | 235 | 0.360 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 73 | 0.360 |
Why?
|
| Cell Line | 7 | 2016 | 1354 | 0.360 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 61 | 0.360 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 225 | 0.350 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 2007 | 7 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2008 | 1618 | 0.340 |
Why?
|
| Tissue Scaffolds | 1 | 2009 | 25 | 0.340 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2009 | 7 | 0.340 |
Why?
|
| In Situ Nick-End Labeling | 5 | 2010 | 133 | 0.340 |
Why?
|
| Penile Diseases | 1 | 2009 | 7 | 0.340 |
Why?
|
| Tunica Media | 1 | 2009 | 12 | 0.340 |
Why?
|
| Prostate | 3 | 2000 | 154 | 0.330 |
Why?
|
| Peripheral Nerves | 1 | 2008 | 14 | 0.330 |
Why?
|
| Imidazoles | 2 | 2006 | 126 | 0.330 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 1502 | 0.320 |
Why?
|
| Muscular Atrophy | 3 | 2003 | 13 | 0.320 |
Why?
|
| Antioxidants | 1 | 2011 | 416 | 0.310 |
Why?
|
| Aorta | 1 | 2009 | 167 | 0.310 |
Why?
|
| Genitalia, Male | 1 | 2007 | 13 | 0.290 |
Why?
|
| PPAR gamma | 1 | 2007 | 53 | 0.290 |
Why?
|
| Sexual Maturation | 3 | 1998 | 23 | 0.290 |
Why?
|
| Pluripotent Stem Cells | 2 | 2003 | 32 | 0.290 |
Why?
|
| Cyclic GMP | 3 | 2018 | 47 | 0.290 |
Why?
|
| Recombinant Proteins | 5 | 2008 | 515 | 0.290 |
Why?
|
| Acetaldehyde | 2 | 2016 | 10 | 0.280 |
Why?
|
| Mice, Knockout | 4 | 2013 | 933 | 0.280 |
Why?
|
| Diabetic Angiopathies | 1 | 2006 | 21 | 0.280 |
Why?
|
| Priapism | 1 | 2006 | 2 | 0.270 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2006 | 23 | 0.270 |
Why?
|
| Base Sequence | 8 | 2006 | 997 | 0.270 |
Why?
|
| Space Flight | 2 | 2002 | 11 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2016 | 1039 | 0.260 |
Why?
|
| Myocytes, Cardiac | 1 | 2007 | 166 | 0.260 |
Why?
|
| Endothelium, Vascular | 3 | 2015 | 237 | 0.250 |
Why?
|
| Electric Stimulation | 4 | 2013 | 184 | 0.250 |
Why?
|
| Enzyme Inhibitors | 5 | 2011 | 433 | 0.250 |
Why?
|
| Dupuytren Contracture | 1 | 2004 | 1 | 0.250 |
Why?
|
| Reproduction | 2 | 2002 | 71 | 0.240 |
Why?
|
| Body Composition | 3 | 2003 | 162 | 0.240 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2003 | 19 | 0.240 |
Why?
|
| Actins | 4 | 2010 | 148 | 0.230 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2014 | 306 | 0.230 |
Why?
|
| Female | 11 | 2020 | 20969 | 0.230 |
Why?
|
| Fibrin | 1 | 2003 | 10 | 0.230 |
Why?
|
| Aromatase | 1 | 2003 | 19 | 0.220 |
Why?
|
| Signal Transduction | 8 | 2015 | 1908 | 0.220 |
Why?
|
| Hypothalamus | 2 | 2001 | 129 | 0.220 |
Why?
|
| Endothelium | 2 | 2016 | 31 | 0.220 |
Why?
|
| Neurons | 3 | 2001 | 1175 | 0.220 |
Why?
|
| Menopause | 1 | 2003 | 56 | 0.220 |
Why?
|
| Organ Size | 5 | 2007 | 157 | 0.210 |
Why?
|
| Administration, Oral | 3 | 2013 | 224 | 0.210 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1198 | 0.210 |
Why?
|
| Myosin Heavy Chains | 1 | 2002 | 19 | 0.210 |
Why?
|
| Transfection | 5 | 2007 | 523 | 0.200 |
Why?
|
| Genes, ras | 3 | 1990 | 25 | 0.200 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 46 | 0.200 |
Why?
|
| Enzyme Induction | 3 | 2009 | 53 | 0.200 |
Why?
|
| Somatomedins | 1 | 2000 | 5 | 0.190 |
Why?
|
| Tyrosine | 1 | 2001 | 118 | 0.190 |
Why?
|
| Kidney | 2 | 2009 | 337 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2010 | 1369 | 0.190 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 626 | 0.190 |
Why?
|
| Urinary Bladder | 1 | 2000 | 29 | 0.180 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 578 | 0.180 |
Why?
|
| Down-Regulation | 5 | 2008 | 435 | 0.180 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2000 | 137 | 0.180 |
Why?
|
| Time Factors | 5 | 2008 | 1742 | 0.180 |
Why?
|
| Electroporation | 3 | 2006 | 18 | 0.180 |
Why?
|
| Up-Regulation | 4 | 2008 | 513 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2016 | 426 | 0.170 |
Why?
|
| Exons | 4 | 1998 | 88 | 0.170 |
Why?
|
| Genetic Vectors | 3 | 2006 | 158 | 0.170 |
Why?
|
| Repressor Proteins | 1 | 2002 | 249 | 0.170 |
Why?
|
| Denervation | 3 | 2007 | 27 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1998 | 8 | 0.170 |
Why?
|
| HIV Wasting Syndrome | 1 | 1998 | 8 | 0.170 |
Why?
|
| Carrier Proteins | 3 | 2008 | 305 | 0.170 |
Why?
|
| Plasmids | 3 | 2006 | 246 | 0.160 |
Why?
|
| Transcription Factors | 3 | 2013 | 681 | 0.160 |
Why?
|
| Molecular Sequence Data | 6 | 2001 | 1568 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 213 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 112 | 0.160 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2008 | 43 | 0.160 |
Why?
|
| Glucocorticoids | 3 | 2003 | 86 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 3 | 2013 | 1609 | 0.150 |
Why?
|
| Adrenal Glands | 1 | 1997 | 19 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 661 | 0.150 |
Why?
|
| Vascular Diseases | 2 | 2007 | 30 | 0.140 |
Why?
|
| Urinary Tract | 1 | 1996 | 8 | 0.140 |
Why?
|
| Ischemia | 1 | 1997 | 46 | 0.140 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1997 | 48 | 0.140 |
Why?
|
| Reactive Oxygen Species | 5 | 2007 | 461 | 0.140 |
Why?
|
| Rats, Inbred BN | 5 | 2005 | 21 | 0.140 |
Why?
|
| Reperfusion Injury | 1 | 1997 | 57 | 0.140 |
Why?
|
| Age Factors | 4 | 2007 | 1033 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 3 | 1996 | 448 | 0.140 |
Why?
|
| Phenotype | 2 | 2009 | 689 | 0.130 |
Why?
|
| Mice, Inbred C3H | 3 | 2005 | 84 | 0.130 |
Why?
|
| Dihydrotestosterone | 3 | 2003 | 29 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1995 | 68 | 0.130 |
Why?
|
| Pentoxifylline | 2 | 2006 | 6 | 0.130 |
Why?
|
| Estrogens | 1 | 2016 | 202 | 0.130 |
Why?
|
| Metalloproteases | 1 | 2014 | 16 | 0.130 |
Why?
|
| Testis | 5 | 2005 | 187 | 0.120 |
Why?
|
| Models, Animal | 3 | 2004 | 134 | 0.120 |
Why?
|
| Blotting, Northern | 3 | 2002 | 150 | 0.120 |
Why?
|
| Carcinoma 256, Walker | 2 | 1988 | 2 | 0.120 |
Why?
|
| Adipose Tissue | 2 | 2005 | 177 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 142 | 0.120 |
Why?
|
| Body Weight | 3 | 2009 | 434 | 0.120 |
Why?
|
| Dexamethasone | 3 | 2003 | 45 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2007 | 617 | 0.110 |
Why?
|
| Mice, Inbred mdx | 1 | 2013 | 5 | 0.110 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2013 | 10 | 0.110 |
Why?
|
| Dystrophin | 1 | 2013 | 19 | 0.110 |
Why?
|
| HIV-1 | 1 | 1998 | 706 | 0.110 |
Why?
|
| beta-Galactosidase | 2 | 2002 | 35 | 0.110 |
Why?
|
| Adenoviridae | 2 | 2002 | 62 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 148 | 0.100 |
Why?
|
| Amino Acid Sequence | 3 | 2000 | 1180 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2006 | 550 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2005 | 366 | 0.100 |
Why?
|
| Estradiol | 1 | 2013 | 262 | 0.100 |
Why?
|
| Nitric Oxide Donors | 1 | 2011 | 18 | 0.100 |
Why?
|
| Allopurinol | 1 | 2011 | 12 | 0.100 |
Why?
|
| Adult | 11 | 2004 | 11712 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2002 | 33 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 807 | 0.100 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2002 | 207 | 0.090 |
Why?
|
| Penile Implantation | 1 | 2010 | 1 | 0.090 |
Why?
|
| Oxidoreductases | 2 | 2004 | 87 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 1989 | 251 | 0.090 |
Why?
|
| Transsexualism | 1 | 2010 | 19 | 0.090 |
Why?
|
| CHO Cells | 2 | 2001 | 124 | 0.090 |
Why?
|
| Uterine Prolapse | 1 | 2009 | 3 | 0.090 |
Why?
|
| Muscle Cells | 1 | 2009 | 11 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2009 | 25 | 0.090 |
Why?
|
| Cricetinae | 2 | 2001 | 238 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 90 | 0.090 |
Why?
|
| Triazines | 2 | 2006 | 20 | 0.090 |
Why?
|
| Veins | 1 | 2009 | 7 | 0.090 |
Why?
|
| Cytokines | 2 | 2004 | 602 | 0.090 |
Why?
|
| Kidney Function Tests | 1 | 2009 | 29 | 0.080 |
Why?
|
| Cloning, Molecular | 3 | 2001 | 325 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 664 | 0.080 |
Why?
|
| Colchicine | 1 | 2008 | 15 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 18 | 0.080 |
Why?
|
| Caspase 2 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Middle Aged | 6 | 2006 | 10129 | 0.080 |
Why?
|
| Aged | 4 | 2004 | 6741 | 0.080 |
Why?
|
| Random Allocation | 1 | 2008 | 139 | 0.080 |
Why?
|
| Insulin | 1 | 2010 | 236 | 0.080 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 122 | 0.080 |
Why?
|
| Smad Proteins | 1 | 2008 | 12 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2008 | 928 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 1988 | 92 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 1989 | 111 | 0.080 |
Why?
|
| Follistatin | 1 | 2008 | 27 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 187 | 0.080 |
Why?
|
| Cryptorchidism | 2 | 1997 | 3 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 116 | 0.070 |
Why?
|
| Video Recording | 1 | 2007 | 32 | 0.070 |
Why?
|
| Orchiectomy | 2 | 1997 | 35 | 0.070 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 1997 | 36 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1988 | 172 | 0.070 |
Why?
|
| Lac Operon | 1 | 2006 | 21 | 0.070 |
Why?
|
| Cell Division | 3 | 2003 | 307 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2007 | 89 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2007 | 110 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2006 | 136 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2005 | 15 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2005 | 22 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 173 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 19 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2006 | 151 | 0.070 |
Why?
|
| MyoD Protein | 1 | 2005 | 9 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2005 | 50 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2005 | 35 | 0.070 |
Why?
|
| Osteoblasts | 1 | 2005 | 35 | 0.070 |
Why?
|
| Azacitidine | 1 | 2005 | 22 | 0.070 |
Why?
|
| beta Catenin | 1 | 2005 | 48 | 0.060 |
Why?
|
| Papaverine | 1 | 2004 | 2 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2009 | 646 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 229 | 0.060 |
Why?
|
| Castration | 1 | 2004 | 34 | 0.060 |
Why?
|
| Androstenedione | 1 | 2004 | 17 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2005 | 90 | 0.060 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2004 | 8 | 0.060 |
Why?
|
| Hypogonadism | 1 | 2004 | 21 | 0.060 |
Why?
|
| Thymosin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Fascia | 1 | 2004 | 3 | 0.060 |
Why?
|
| Germ Cells | 1 | 2005 | 73 | 0.060 |
Why?
|
| HIV Infections | 1 | 1998 | 2303 | 0.060 |
Why?
|
| Cortactin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Xanthine Oxidase | 1 | 2004 | 8 | 0.060 |
Why?
|
| Injections | 1 | 2004 | 35 | 0.060 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 75 | 0.060 |
Why?
|
| Mutation | 1 | 1989 | 1095 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 286 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 1 | 2004 | 5 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 48 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2004 | 69 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2003 | 70 | 0.060 |
Why?
|
| Inflammation | 1 | 2009 | 618 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 75 | 0.060 |
Why?
|
| Weightlessness Simulation | 2 | 2000 | 21 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 60 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2003 | 20 | 0.060 |
Why?
|
| Ligands | 2 | 2004 | 349 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2003 | 129 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2002 | 30 | 0.050 |
Why?
|
| Vimentin | 1 | 2002 | 37 | 0.050 |
Why?
|
| Disease Progression | 1 | 2005 | 601 | 0.050 |
Why?
|
| Peroxynitrous Acid | 1 | 2002 | 6 | 0.050 |
Why?
|
| Pancreatic Elastase | 1 | 2002 | 7 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2002 | 10 | 0.050 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2002 | 7 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 168 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2002 | 29 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 562 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 77 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2001 | 49 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2002 | 105 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2002 | 78 | 0.050 |
Why?
|
| Oxytocin | 1 | 2001 | 25 | 0.050 |
Why?
|
| RNA | 1 | 2003 | 241 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2002 | 85 | 0.050 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2000 | 23 | 0.050 |
Why?
|
| Ubiquitins | 1 | 2000 | 46 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2000 | 59 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2000 | 69 | 0.050 |
Why?
|
| Expert Testimony | 2 | 2010 | 5 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 252 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2002 | 53 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2000 | 66 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2000 | 114 | 0.040 |
Why?
|
| Bed Rest | 1 | 1999 | 3 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2000 | 130 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 97 | 0.040 |
Why?
|
| Sex Factors | 1 | 2003 | 898 | 0.040 |
Why?
|
| Drosophila | 1 | 2001 | 144 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 1999 | 32 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2003 | 1418 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2003 | 1378 | 0.040 |
Why?
|
| Thiourea | 1 | 1978 | 5 | 0.040 |
Why?
|
| Introns | 1 | 1998 | 75 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 935 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 188 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 539 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2001 | 453 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 1978 | 133 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2000 | 387 | 0.040 |
Why?
|
| Citrulline | 1 | 1997 | 10 | 0.040 |
Why?
|
| DNA | 1 | 2001 | 574 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 1997 | 25 | 0.040 |
Why?
|
| Pregnatrienes | 1 | 1997 | 1 | 0.040 |
Why?
|
| Cattle | 1 | 1998 | 477 | 0.040 |
Why?
|
| Aldosterone | 1 | 1997 | 66 | 0.040 |
Why?
|
| Seminiferous Tubules | 1 | 1996 | 8 | 0.040 |
Why?
|
| Cotinine | 1 | 1997 | 43 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 1997 | 78 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 474 | 0.040 |
Why?
|
| Nicotinic Agonists | 1 | 1997 | 75 | 0.030 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 1996 | 1 | 0.030 |
Why?
|
| Finasteride | 1 | 1996 | 4 | 0.030 |
Why?
|
| Rats, Inbred BB | 1 | 1995 | 3 | 0.030 |
Why?
|
| Drug Implants | 1 | 1995 | 21 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 86 | 0.030 |
Why?
|
| Cytosol | 1 | 1996 | 93 | 0.030 |
Why?
|
| Reflex | 1 | 1995 | 34 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 43 | 0.030 |
Why?
|
| Adolescent | 2 | 2003 | 5363 | 0.030 |
Why?
|
| Child | 1 | 2003 | 3131 | 0.030 |
Why?
|
| Liver | 1 | 1978 | 479 | 0.030 |
Why?
|
| Prevalence | 2 | 2010 | 1455 | 0.030 |
Why?
|
| 3T3 Cells | 2 | 2005 | 59 | 0.030 |
Why?
|
| Nicotine | 1 | 1997 | 257 | 0.030 |
Why?
|
| Reference Values | 2 | 2004 | 212 | 0.030 |
Why?
|
| Codon | 2 | 1989 | 42 | 0.030 |
Why?
|
| Kinetics | 2 | 2004 | 708 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1991 | 45 | 0.030 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 133 | 0.030 |
Why?
|
| Templates, Genetic | 1 | 1990 | 25 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1990 | 37 | 0.020 |
Why?
|
| Penile Prosthesis | 1 | 2010 | 1 | 0.020 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2010 | 2 | 0.020 |
Why?
|
| Brain | 1 | 1998 | 1346 | 0.020 |
Why?
|
| Amputation, Traumatic | 1 | 2010 | 1 | 0.020 |
Why?
|
| Sexology | 1 | 2010 | 1 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 3 | 0.020 |
Why?
|
| Replantation | 1 | 2010 | 2 | 0.020 |
Why?
|
| Urology | 1 | 2010 | 7 | 0.020 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 22 | 0.020 |
Why?
|
| Medicine | 1 | 2010 | 33 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1989 | 6 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 191 | 0.020 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1989 | 23 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1988 | 20 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1989 | 93 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 164 | 0.020 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2008 | 16 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2008 | 30 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 77 | 0.020 |
Why?
|
| Aldehydes | 1 | 2008 | 69 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 1988 | 153 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 3562 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 152 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2006 | 233 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2006 | 155 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 1988 | 312 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2004 | 34 | 0.020 |
Why?
|
| Protein Transport | 1 | 2005 | 302 | 0.020 |
Why?
|
| Plasminogen Inactivators | 1 | 2004 | 3 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 36 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 218 | 0.010 |
Why?
|
| Receptors, Somatotropin | 1 | 2003 | 12 | 0.010 |
Why?
|
| Physical Exertion | 1 | 2003 | 26 | 0.010 |
Why?
|
| Tosyl Compounds | 1 | 2003 | 2 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 18 | 0.010 |
Why?
|
| Arteries | 1 | 2004 | 65 | 0.010 |
Why?
|
| Anilides | 1 | 2003 | 28 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 103 | 0.010 |
Why?
|
| Mifepristone | 1 | 2003 | 34 | 0.010 |
Why?
|
| Nitriles | 1 | 2003 | 69 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2003 | 34 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 444 | 0.010 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2002 | 7 | 0.010 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 2002 | 10 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 360 | 0.010 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2002 | 11 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2002 | 32 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2001 | 22 | 0.010 |
Why?
|
| DNA Probes | 1 | 2001 | 29 | 0.010 |
Why?
|
| Pituitary-Adrenal System | 1 | 2002 | 39 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 286 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2001 | 62 | 0.010 |
Why?
|
| United States | 1 | 2010 | 4223 | 0.010 |
Why?
|
| Head-Down Tilt | 1 | 1999 | 4 | 0.010 |
Why?
|
| Thyroxine | 1 | 1999 | 19 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1999 | 17 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 307 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2003 | 854 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 481 | 0.010 |
Why?
|
| Gene Amplification | 2 | 1989 | 26 | 0.010 |
Why?
|
| Leukemia L1210 | 1 | 1978 | 1 | 0.010 |
Why?
|
| Puromycin | 1 | 1978 | 2 | 0.010 |
Why?
|
| Isothiuronium | 1 | 1978 | 3 | 0.010 |
Why?
|
| Ribosomes | 1 | 1978 | 32 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1978 | 26 | 0.010 |
Why?
|
| RNA, Transfer | 1 | 1978 | 28 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1978 | 71 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1978 | 409 | 0.010 |
Why?
|
| Rats, Mutant Strains | 1 | 1996 | 6 | 0.010 |
Why?
|
| Atrophy | 1 | 1996 | 42 | 0.010 |
Why?
|
| Nitrites | 1 | 1993 | 46 | 0.010 |
Why?
|
| Nitrates | 1 | 1993 | 40 | 0.010 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 1989 | 1 | 0.010 |
Why?
|